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Abstract
Chemotherapy is often administered in openly designed hospital wards, where the possibility
of patient–patient social inﬂuence on health exists. Previous research found that social
relationships inﬂuence cancer patient’s health; however, we have yet to understand social
inﬂuence among patients receiving chemotherapy in the hospital. We investigate the inﬂuence
of co-presence in a chemotherapy ward. We use data on 4,691 cancer patients undergoing
chemotherapy in Oxfordshire, United Kingdom who average 59.8 years of age, and 44% are
Male. We construct a network of patients where edges exist when patients are co-present
in the ward, weighted by both patients’ time in the ward. Social inﬂuence is based on total
weighted co-presence with focal patients’ immediate neighbors, considering neighbors’ 5-year
mortality. Generalized estimating equations evaluated the eﬀect of neighbors’ 5-year mortality
on focal patient’s 5-year mortality. Each 1,000-unit increase in weighted co-presence with a
patient who dies within 5 years increases a patient’s mortality odds by 42% (β = 0.357,
CI:0.204,0.510). Each 1,000-unit increase in co-presence with a patient surviving 5 years
reduces a patient’s odds of dying by 30% (β = −0.344, CI:−0.538,0.149). Our results suggest
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that social inﬂuence occurs in chemotherapy wards, and thus may need to be considered in
chemotherapy delivery.
Keywords: medicine, public health, chemotherapy, longitudinal network, communal coping,
generalized estimating equation, jaccard index, administrative data
1 Introduction
Cancer is a leading cause of death in the United Kingdom, with one in four people
dying of cancer (UK Cancer Research, 2014). Cancer patient outcomes, particularly
the gold-standard 5-year survival, have been robustly associated with a number of
individual characteristics such as treatment protocol, age, sex, and cancer severity
(Bossard et al., 2007; Coleman et al., 2011; Siegel et al., 2015). A patient’s social
sphere may also impact patient outcomes: there is evidence, for example, that social
ties (e.g., increased social network size and interactions) are associated with both
reduced all-cause mortality and cancer-speciﬁc mortality, and that this relationship
may be stronger for women (Ernst et al., 1992; Holt-Lunstad et al., 2010; Shor &
Roelfs, 2015). However, there is limited research considering the eﬀect of the social
context of cancer treatment itself on patient survival. Indeed, chemotherapy—one
of the most common forms of treatment—is often administered in outpatient group
settings, representing one important social context for further inquiry. To this end,
we investigate the impact of network members’ co-presence, survivorship, and death
on individual chemotherapy patients’ survival.
1.1 Stress-mediated eﬀect of social inﬂuence on health
Social inﬂuence may be an important interpersonal mechanism impacting health
outcomes of cancer patients receiving treatment in the chemotherapy ward through
patients’ stress response. Patients entering chemotherapy generally have three con-
comitant threats to their health: the physical disease of the cancer, the neuro-
endocrine stress based on uncertainty related to the course of the physical disease,
and the cellular response to chemotherapy (Maria et al., 2004; Tiligada, 2006).
Although the cancer itself is the major cause of mortality, the eﬀects of stress on
health are also important; reduced stress can signiﬁcantly reduce 5-year mortality in
chemotherapy patients (Cohen, 1988). Therefore, if stress is altered by some social
inﬂuence process, then such processes can impact overall health and survival of
cancer patients. A spectrum of social inﬂuence mechanisms exists, each distinguished
by variation in the type of interaction.
Each has diﬀerent implications for how social inﬂuence may impact the patient’s
stress response. The strongest eﬀects of social inﬂuence are in the context of direct
interactions with close social ties (Beaton et al., 2008; Holt-Lunstad et al., 2010). This
work generally considers the exchange of social resources, including informational,
emotional, and instrumental support (Cobb, 1976; House, 1987). There are a number
of robust associations between the structure and function of patients’ social support
networks, patients’ stress response, and ultimately their health outcomes. These
include the strength of ties (Orth-Gomer & Johnson, 1987; Yang et al., 2016),
received social support (Luszczynska et al. 2007), and perceived social support (Yang
et al., 2016). Such support resources have been shown to inﬂuence how patients with
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a health stressor manage that stress (Berg et al., 2008). For example, Croyle &
Hunt (1991) showed that patients experienced diﬀerent responses to a medical test
result based on whether or not they interacted with a confederate receiving the
same test result; those receiving similar results experienced lower stress levels than
those that diﬀered. However, not all social interactions result in positive outcomes.
For instance, patients can also support one another via an exchange of information
(Frost & Massagli, 2008), but if the information is poor, one’s perception of the
sharer’s knowledge is negative, or the relationship between network members itself
is negative; the health outcomes of this interaction can be deleterious (McKinlay,
1973; Rook, 1984).
Social inﬂuence may also occur in the absence of direct interaction. A patient’s
physical appearance, for example, may convey information about their true health
status, which other patients observe; such information can impact, in turn, the
observer’s health. Previous research has shown that the mere presence of others
engaged in the same task impacts physiological arousal and performance, in what is
known as social facilitation (Zajonc, 1965). Also, individuals will alter their behavior
based on the behavior of those around them, in what is known as modeling (De La
Haye et al., 2011). While there is not a speciﬁc behavior or task in chemotherapy,
one still observes others responding well or poorly to treatment over time. These
observed responses could then eﬀect arousal or stress pathways, resulting in indirect
inﬂuence dependent on the outcomes of the observed patients. Both social facilitation
and modeling can therefore result in diﬀerences in behavior and stress response that
ultimately impact health.
Finally, it is important to note that these social processes may result in diﬀerential
stress responses based on whether the relationship in question is with a stranger or
a familiar individual. For example, one study found that people had slower latent
cognitive reaction times based on functional Magnetic Resonance Imaging (fMRI)
when presented with a familiar face when compared to an unfamiliar face. Such
responses likely indicate increased arousal for participants when observing familiar
faces (Beaton et al., 2008), a result previously found in animal models (Armario et
al., 1983). Thus, observing familiar people elicits diﬀerent reactions than observing
strangers. In the setting of chemotherapy, patients almost always begin as strangers,
but may become more familiar over time (whether through direct interaction or ob-
servation and mitigated through a process of consistently being co-present together),
and those who do become familiar may exert stronger inﬂuence on one another.
1.2 Social inﬂuence in other social contexts for chemotherapy patients
There is strong evidence to suggest that social inﬂuence can impact stress and
therefore health outcomes through a variety of interpersonal processes. Much of
the research investigating social inﬂuence processes in cancer patients has involved
patients in settings outside the chemotherapy ward. For example, couples support
one another when one member has developed cancer. Although only one member is
aﬀected by cancer, both experience stress due to the diagnosis and both are likely to
engage adaptive changes to the stress by supporting each other (Berg et al., 2008). In
this context, couples have a pre-existing relationship in which members intimately
know and support each other prior to the cancer diagnosis.
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There is also a large body of evidence that member of cancer social support
groups beneﬁt from exchange of social support resources (Cain et al., 1986). While
patients in cancer support groups likely do not know each other prior to joining the
group, patients join such groups because they are seeking and in need of support
from experientially similar others. Additionally, all patients entering into cancer
support groups self-identify as persons with cancer, which can enhance the social
interactions with other, like-minded individuals. This is particularly important, as
those with similar experiences are ideally situated to inﬂuence others’ stress buﬀering
via emotional sustenance, assistance in active coping, or role modeling (Thoits, 2011).
Such support groups represent a context in which patients form a rapport de novo,
followed by subsequent strengthening or weakening of their relationship.
In contrast, patients within the chemotherapy ward may or may not be actively
seeking social support from others receiving chemotherapy; their primary purpose
is cancer treatment. Any social exchange occurring while receiving chemotherapy
is secondary to treatment. However, the chemotherapy ward is an important social
context to investigate whether social inﬂuence naturally occurs, and if so, what
impact such inﬂuence has on patients’ health outcomes. We hypothesize that social
inﬂuence can be both positive and negative. For example, we would expect that pos-
itive patient outcomes, such as cancer survivorship, would positively impact patients
receiving treatment together. However, negative patient outcomes, such as physical
decline and death, may negatively impact the survivorship of patients receiving
treatment together. The latter proposition is based on evidence indicating that the
death of a close network member, such as a spouse, likely accelerates one’s own
mortality (Elwert & Christakis, 2008; Mineau et al., 2002). More generally, previous
research has shown that disruption in one’s social network can adversely aﬀect
psychological distress that can lead to adverse health outcomes (Oyama et al., 2012;
Perry, 2016). Noticing that familiar patients are no longer in the chemotherapy ward
(due to death or successfully ﬁnishing chemotherapy) may have similar eﬀects if one
considers those others as members of their social network. Thus, the chemotherapy
setting represents an ideal context to investigate the inﬂuence of patient outcomes
and network disruption on survivorship and whether such inﬂuence can occur when
neither pre-existing social ties nor an explicit desire for social support are present.
1.3 Social networks
Past research has alluded to the role of social network resources in cancer patients’
health trajectories, but has not made use of sociometric data, primarily due to the
cost and diﬃculty associated with its procurement. These studies have predominantly
focused on very small networks of couples (Oberst et al., 1989), been primarily
qualitative (Wolf, 2015), or have used data from a subset of the people represented in
the network (Koehly et al., 2011). However, all of these studies build the evidence base
that the connections between people within a network have important implications
for social inﬂuence processes that facilitate cancer patients’ adaptation to their
diagnosis and treatment. Moreover, there is a breadth of research showing that
social inﬂuence is impacted by network structure for a variety of health outcomes,
and this is robust across age, race, and socio-economic status (Christakis & Fowler,
2007; Mercken et al., 2012; Perkins et al., 2014; Valente et al., 2003). Indeed, this body
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of research focuses primarily on established social relationships or support group
settings and shows that inﬂuence does not depend solely on individual, independent
dyads or a direct social connection, but that the overall structure of the network
is important. There are methodological issues when examining inﬂuence processes
within such contexts—diﬀerentiating between selection or inﬂuence is generally
diﬃcult—limiting the types of inferences one can make (Shalizi & Thomas, 2012;
VanderWeele, 2011). However, the chemotherapy ward is not a context within which
one self-selects or chooses partners, providing a unique opportunity to evaluate
inﬂuence processes with a limited possibility for social selection bias.
1.4 Research questions and hypotheses
In the current paper, we investigate the inﬂuence of cancer patient health outcomes
on individual 5-year survival in a longitudinal chemotherapy treatment co-presence
network. We do so in the context of the chemotherapy ward, where patients are
unlikely to have previous social ties with others in the ward, and who are not
present primarily to seek social support. Despite this, there is ample opportunity for
social inﬂuence to occur either directly via the exchange of social support resources
or indirectly by consistent observation of other patients’ health changes over time.
As such, health outcomes of those with whom cancer patients are consistently
co-present can potentially inﬂuence individual patient outcomes. To this end, we
investigate whether co-presence between chemotherapy patients is associated with
survival and whether such inﬂuence mechanisms vary by sex (Shor & Roelfs, 2015).
2 Data and methods
Our data come from the Infections in Oxfordshire Research Database, which is
composed of standard National Health Service (NHS) administrative records. This
data set was originally established to monitor infectious diseases (e.g., recording
full genotyping of infectious agents), and also contains complete individual health
records. The data for our analysis comprises all 4,691 patients in the hospital’s
single outpatient chemotherapy ward from Jan 1, 2000 to Jan 1, 2009. We exclude
49 patients who received chemotherapy for conditions unrelated to cancer (e.g.,
for multiple sclerosis). Our data also include 109 left-censored cases (representing
2% of cases) who were already receiving chemotherapy at the time data collection
began. Each patient’s medical history is broken into individual visitation spells (n =
43,898) in the chemotherapy ward with time stamps for both entry and exit. A
chemotherapy spell is deﬁned as every occurrence with unique entry and exit times
of any patient into the chemotherapy ward. The date of death is also recorded for
each individual through June, 2015.
2.1 Chemotherapy ward and process of treatment
As an outpatient setting, the chemotherapy ward was open between 8 a.m. and 8
p.m. from Monday through Friday. The ward was split into two treatment rooms,
containing 10 beds and 6 chairs, respectively, arranged in a circle (Figure 1). The
beds were ﬁtted with a screen that could be drawn when privacy was desired. Other
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Fig. 1. Layout of the chemotherapy ward. Patients begin spells in the waiting room, and are
taken to either treatment room 1 or 2 depending on a number of factors.
than that, all patients in the same treatment room were in view of one another for
the duration of treatment. Upon arriving to the ward, patients began in the waiting
room and underwent bloodwork to ensure eligibility for chemotherapy. This was
typically done on the day of treatment, but could be done the day before. Depending
on the results of the blood test, chemotherapy could commence, be postponed, or
canceled.
Chemotherapy regimens are stringent in the timing of doses. The timing of a
patient’s initial dose is based on the importance of immediate treatment, availability
in the ward and patient preference. Once the ﬁrst treatment is scheduled, the rest
of the treatments follow a standard schedule, with a few hours of variation on
any given day depending on patient availability. Therefore, patients with whom one
overlaps are primarily determined by who is in the ward at the time of the initial
dose, and the prescribed timing of chemotherapy. This informs pairs of individuals
for which we consider inﬂuence possible.
2.2 Co-presence network construction
The network of interest represents patient co-presence in the chemotherapy ward.
Because we want the connections to represent quantities of co-presence with the
potential for social inﬂuence, and no measure perfectly captures all the dimensions
we think are important for social inﬂuence, we use two diﬀerent methods for
determining co-presence. The primary network measure is the Jaccard index, the
matrix of which is deﬁned as the intersection of the two patients’ treatment times
divided by the union of these patients’ treatment times. In other words
Jij =
|H (i) ∩ H (j)|
|H (i) ∪ H (j)| ,
where H(i) is a function that returns the set of hours patient i spent in the
chemotherapy ward during the course of their treatment, and its magnitude is
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the total number of hours patient i spent in the ward. We subset the denominator
based on the time patients i and j could have spent together; i.e., when they are both
alive and undergoing chemotherapy. This gives a quantitative measure of how often
i and j were together relative to how often they could have been together, resulting
in a weighted and undirected network such that Jij = Jji, and Jij = 0 indicates 0
hours of overlap between i and j.
However, the Jaccard index has some limitations. One such limitation is its
lack of sensitivity to total patient chemotherapy hours; when two patients overlap
and are only in the ward for a single spell, their Jaccard index is very high and
indistinguishable from two patients who are repeatedly in the ward together over
time. This is evident in the large peak in the empirical density of the Jaccard index
at one (Figure S1). Of those, 1,762 Jaccard indices stem from single-visit overlaps.
To address this, we up-weight the Jaccard index by the hours spent in the ward by
the focal patient (see independent variables). As a second limitation, the Jaccard
index proposes that even an hour of co-presence can result in social inﬂuence. It is
our belief that this is not theoretically likely. We address this potential issue by also
constructing a network based on consistent co-presence—that is, we create an edge
when two patients overlap more than expected by chance, which has the beneﬁt of
deﬁning a baseline expectation for overlap given ward scheduling. This method and
the parallel analyses are presented in the Supplementary Information (see Figure S2
and Table S1, Model A).
2.3 Dependent variable
Our primary outcome is a patient’s 5-year mortality, which is the gold-standard in
cancer survivorship research and practice (Bossard et al., 2007). Patients’ outcomes
were measured at the end of treatment by recording the last chemotherapy session
followed by a 6-month period with no visit to the chemotherapy ward. The outcome
was recorded 1 = death if they died within 5-years of their end of treatment date and
had a diagnosis of cancer at the hospital spell most temporally proximate to their
date of death (i.e., count as censored patients who die of causes unrelated to their
cancer), and 0 = survival otherwise. Because the chemotherapy data ends in 2009,
and we have death data through mid-2015, there is no administrative censoring for 5-
year survival—we treat de facto right-censoring after 2015 simply as 5-year survival.
2.4 Independent variables
1-path Inﬂuence. As previously noted, complete overlap of treatment, whether over
1 or 100 hours, will result in equivalent Jaccard indices. We, therefore, weight the
Jaccard index by the number of hours the focal patient spent in the ward. We call
this the Jaccard-weighted person-hours, which diﬀerentiate overlap of only a few
hours from that of many hours while still adjusting for the relative potential for
overlap by any two patients. The Jaccard-weighted person-hours for a focal patient
can be written as:
JW (i) = |H(i)|∑
j
Jij , j = i.
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This total count is then partitioned into the Jaccard-weighted person-hours with
directly-connected patients who survived at least 5 years following chemotherapy
(JWS1P ) and with those who died within 5 years following chemotherapy (JWD1P ),
allowing us to separate their relevant eﬀects and understand more about underlying
inﬂuence mechanisms. These can be written as:
JWS1P (i) = |H(i)|∑
j
(
Jij ∗ S(j)), j = i
JWD1P (i) = |H(i)|∑
j
(
Jij ∗ (1 − S(j))), j = i,
where S(j) is equal to one if patient j survived at least 5 years following their
chemotherapy and zero otherwise.
2-path Inﬂuence. Although we a priori expect the inﬂuence to be between directly-
connected patients only, we include 2-path inﬂuence variables representing the
sum of Jaccard-weighted person-hours for paths to non-adjacent patients two-steps
away from the focal patient based on their outcomes (survival or death) as a
negative control. While it is possible that a patient two-steps away may inﬂuence
a directly-connected patient, we believe there would be no inﬂuence independent
of the mediating patient, and such an eﬀect should be non-signiﬁcant. When an
open 2-path exists, it means that the patients without an edge did not overlap
at all, despite being in chemotherapy around the same time (as evidenced by
their common overlap with a third patient). This would occur when the start and
end patients just missed each other temporally in the ward, most likely reﬂecting
random scheduling variation based on patient or ward availability. The start and
end patients in the 2-path would, therefore, be in the ward together were it not for
random chance. Additionally, because they both overlap with similar patients, any
latent characteristics leading to co-presence would also likely be similar. Although a
signiﬁcant result for these covariates could be due to either latent similarity between
patients two-steps away or due to inﬂuence over two steps in the network, the
lack of a signiﬁcant result indicates that neither of these mechanisms are likely at
work ceteris paribus. We, therefore, construct the variables as total weight of open
two-paths between a focal patient and another patient based on whether the other
patient survived (JWS2P ) or died (JWD2P ). Weights of the open 2-paths were equal to
the product of the two individual edge weights on the path. These can be written as:
JWS2P (i) = |H(i)|∑
j
∑
k
(
Jij ∗ Jjk ∗ S(k) ∗ Mik), j = i, k
JWD2P (i) = |H(i)|∑
j
∑
k
(
Jij ∗ Jjk ∗ (1 − S(k)) ∗ Mik), j = i, k,
where Mik equals 1 when i and k are not directly connected in the co-presence
network (i.e., they are never co-present), and zero when they are.
2.5 Covariates
A number of covariates are included in our ﬁtted models as controls for other
sources of heterogeneity. First, we include patient sex and the age of the patient
at the start of chemotherapy. In addition, we control for variables related to the
chemotherapy treatment itself. These include the number of visits to the ward
during the chemotherapy cycle and the total time in the ward over all ward visits.
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As well, we include the timing with respect to the 10 years of observation of when
each patient began their chemotherapy, allowing us to control for any exogenous
changes to survival as treatment improved over time. We also control for the total
person-hours of overlap each patient had with all others in the ward. Finally, we
add two terms to the model for the interaction between patient sex and the direct
path Jaccard-weighted person-hour statistics.
To account for the eﬀect of disease severity on 5-year survival we include variables
derived from the ICD-10 codes (C00-C99) on patients’ health records (WHO, 1992).
Previous studies largely focused on a single type of cancer and adjust for the disease
stage (Kroenke et al., 2006). No studies could be found that adjusted for the severity
of cancer across primary cancer sites, giving us no basis from past literature for which
to adjust for disease severity. Thus, we generalized past approaches by including all
primary cancer types as a series of dummy variables, one for each observed cancer
type, for a total of 20 variables, with pancreatic cancer as the arbitrary baseline.
Empirical 5-year survival in these data ranged from 7% of patients for brain cancer
to 94% for prostate cancer, indicating a large variance in basal prognosis with
respect to the location of the primary cancer (UK Cancer Research, 2014). Patients
that were recorded as having non-speciﬁc, ill-deﬁned, secondary, or miscellaneous
multiple sites (i.e., from ICD codes C76, C77, C78, C79, C80, C97) were given their
own dummy variable as these cancers are typically more rare and more diﬃcult to
treat (Shibuya et al., 2002).
Although the ICD-10 code does not explicitly diﬀerentiate between stages of
cancer, we can distinguish Stage IV, the most severe cases, where the neoplasm
has aggressively spread to a second tissue with a secondary cancer diagnosis
(metastasized) (AJCC, 2017). We include an indicator variable for any secondary
cancer diagnoses during a patient’s treatment as a proxy for metastasis. Left-censored
patients (n = 145) had this variable imputed based on the full-data set as a function
of a patient’s covariates. Model checking diagnostics revealed that our results were
robust to this imputation.
Finally, we control for the admitting consultant physician. The admitting con-
sultant physician can induce latent homophily among patient outcomes, if their
patients are placed together in the ward and survival outcomes are similar due to
either shared physician treatment decision strategies or because patients have similar
cancer types. For every spell, an admitting consultant physician is assigned—these
physicians generally specialize in a given cancer type. Over the 9-year period of the
study, there were a total of 73 admitting consultant physicians. However, only 24
of them saw at least 10 diﬀerent patients. To retain model parsimony and avoid
degeneracy, we included 24 indicator variables for these physicians. The referent
group is therefore those patients who saw one of the 49 admitting physicians with
less than 10 chemotherapy patients. For parsimony and space, we show only the
physician with the largest positive and negative signiﬁcant eﬀects.
2.6 Analysis
To evaluate our hypotheses that social inﬂuence in a chemotherapy ward impacts
patient mortality, we ﬁt a series of Generalized Estimating Equations (GEEs) to
account for the repeated measures of individuals with multiple chemotherapy cycles.
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We use a binomial variance with a logit link function to estimate the probability
that an individual dies within 5 years of their last treatment. We ﬁt several models
using a step-wise blocked variable design. In our ﬁrst block (Model 1), the outcome
is modeled as a function of focal actor age, gender, time of chemotherapy cycle,
number of treatment spells, the prognosis rank of cancer with which the patient
was diagnosed, whether an individual had multiple tumor diagnoses (proxy for
metastasis), total hours in the ward, and total person-hours of overlap with other
patients. We then added the direct inﬂuence eﬀects (Model 2) and then the indirect
inﬂuence eﬀects, or open two-paths (Model 3). Finally, as previously stated, patient
sex may moderate the relationship between social contact (Shor & Roelfs, 2015).
We, therefore, add interaction terms between the inﬂuence eﬀects and whether the
focal patient is male or female (Model 4).
We also conducted a number of robustness checks on this analysis and report
the results in the Supplemental Information. Brieﬂy, due to the issue previously
discussed with the Jaccard-weighted person-hours, we dichotomize patient–patient
overlap, calling signiﬁcant any overlap that is more than expected by chance
between two patients (p¡0.01) (Table S1 Model A, Figure S1). We also believe
that a more parsimonious model could be created by treating cancer severity as
a single continuous variable based on population-level cancer-speciﬁc death rates
for patients in the United Kingdom. Thus, we report results using this alternative
construction of cancer-severity in the supplement (Table S1 Model B). As well, we
recognize that the GEE does not address latent confounding between connected
individuals in a network, so we reran Model 2 (our main model) using bootstrapped
samples of unconnected patients (Table S1 Model C). Because we have precise
survival times, we ﬁt a Cox proportional hazards model to our data (Table S1
Model D). Finally, although we have no data on the nurses assigned to patients,
we conducted a sensitivity analysis in which we assume a patient’s primary nurse is
a probabilistic function of both the nurses of their neighbors and their own health
outcomes (and indirectly the health outcomes of their neighbors) (Figure S3).
3 Results
Table 1 reports the descriptive statistics of the sample. The 4,691 chemotherapy
patients from Jan 1, 2000 to Jan 1, 2009 had a mean age of 59.8 (SD = 13.1), and
44% (n = 2,094) were male. The patients underwent a total of 43,898 chemotherapy
spells, which consisted of an average of 8.5 (SD = 10.9) visits to the chemotherapy
ward per spell with each visit lasting, on average, 4.0 hours (SD = 5.3). Two-thirds
of the patients had a single diagnosis of cancer (n = 3, 122), 994 had two diagnoses,
and one patient had nine diagnoses. With respect to location of the cancer, 1,108
patients were diagnosed with breast cancer—the most common cancer diagnosis—
treated in the chemotherapy ward with a 5-year survival of 91% (based on UK
statistics). Almost 500 patients were diagnosed with lung cancer; lung cancer is the
second most severe cancer type with a 5-year survival of only 18% in the United
Kingdom. A total of 850 people had a diagnosis of unspeciﬁed or multiple cancers
that could not be classiﬁed to a single location. Finally, the 145 patients who were
left-censored and therefore had no recorded cancer diagnoses had imputed values
between 1.21 and 1.54 cancer diagnoses.
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Table 1. Demographic characteristics of the 4,691 patients receiving chemotherapy at any time
from Jan 1, 2000 to Jan 1, 2009.
Variable Mean (SD) or n (%)
Age 59.79 (13.00)
Male 2094 (44%)
Number of ward visits during cycle 8.51 (10.94)
Time of chemotherapy cycle (years) 0.32 (0.48)
Average time in ward per spell (hours) 3.95 (5.32)
Number of cancer diagnoses 1.30 (0.63)
Primary cancer diagnosis
Breast 1108 (24%)
Lung 443 (9%)
Pancreas 125 (3%)
Unspeciﬁed 850 (18%)
Other 2165 (46%)
Diagnosed with unspeciﬁed cancer 297 (6%)
Number of patients co-present with 113.91 (122.18)
Total person-hours of overlap 1012.66 (1,997,599)
JI∗S1P 6.50 (7.75)
JI∗D1P 10.67 (11.35)
JI∗S2P 238.52 (243.60)
JI∗D2P 385.01 (381.07)
JWS1P 697.94 (2,237.04)
JWD1P 1,118.61 (3,378.28)
JWS2P 23,027.58 (61,611.72)
JWD2P 34,657.70 (103,809.80)
∗The JI terms are the JW terms divided by the person-hours of
chemotherapy of the focal patient. In other words, they are the sum
of the respective 1- or 2-path Jaccard indices for each focal actor.
The mean total Jaccard index for neighbors’ survival was 6.50 (SD = 7.75)
(Table 2, JIS1P ). The mean total Jaccard index for neighbors’ death was 10.67
(SD = 11.35) (JIS1D). With respect to 2-paths for neighbors’ survival or neighbors’
death, the means were 238.52 (SD = 243.60) and 385.01 (SD = 385.01), respectively
(JIS2P and JIS2P ). The mean total Jaccard-weighted person-hours for neighbors’
survival was 698 (SD = 2, 237) (JWS1P ). The mean total Jaccard-weighted person-
hours for neighbors’ death was 1,118 (SD = 3, 378) (JWD1P ). With respect to 2-paths
for neighbors’ survival or neighbors’ death, the means were 21,027 (SD = 61, 611)
and 34,658 (SD = 103, 810), respectively (JWS2P and JWD2P ). Thus, patients were
more likely to experience deaths of co-present alters than survivorship; a similar
pattern was observed for indirect ties through two-paths.
Results based on the GEEs using Jaccard-weighted person-hours are presented
in Table 2. Being older, male, or having more severe cancer was associated with
increased likelihood of death across all models (Model 1). This is consistent with
previous literature and trends in cancer survival. The number of ward visits during
a chemotherapy cycle and the total time of the cycle were not signiﬁcant predictors
of death. Additionally, the later in the study period a person began chemotherapy,
the better their chance of survival, indicating a trend toward better treatment over
time.
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Table 2. Results of generalized estimating equations modeling inﬂuence via Jaccard index. The model outcome is death within 5 years of ending chemotherapy.
We used a binomial variance with logistic link function, and an unstructured covariance matrix for repeated outcomes on individuals.
Model 1 Model 2 Model 3 Model 4
Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
Variable Residuals2 = 871.7 Residuals2 = 859.6 Residuals2 = 857.6 Residuals2 = 854.8
Intercept 1.166 (0.166, 2.167) 1.257 (0.251, 2.263) 1.28 (0.275, 2.286) 1.266 (0.259, 2.272)
Age (years) 0.038 (0.032, 0.044) 0.038 (0.032, 0.044) 0.038 (0.032, 0.044) 0.038 (0.032, 0.044)
Sex (male) 0.216 (0.029, 0.404) 0.22 (0.032, 0.408) 0.219 (0.031, 0.408) 0.28 (0.083, 0.478)
Time of cycle (years) −0.316 (−0.561, −0.071) −0.351 (−0.608, −0.095) −0.315 (−0.579, −0.051) −0.359 (−0.626, −0.092)
Number of visits in course 0.003 (−0.009, 0.015) −0.006 (−0.019, 0.007) −0.01 (−0.024, 0.005) −0.009 (−0.023, 0.006)
Years after 2000 patient begins
chemotherapy
−0.123 (−0.16, −0.086) −0.122 (−0.159, −0.084) −0.121 (−0.159, −0.083) −0.121 (−0.159, −0.083)
Total person-hours of overlap 0.01 (−0.001, 0.001) 0.001 (−0.001, 0.001) 0.001 (−0.001, 0.001) 0.001 (−0.001, 0.001)
More than one cancer diagnosis 1.177 (0.528, 1.826) 1.19 (0.535, 1.845) 1.197 (0.542, 1.851) 1.192 (0.536, 1.848)
JWS1P (per 1,000 person-hours) −0.346 (−0.540, −0.152) −0.282 (−0.536, −0.027) −0.336 (−0.615, −0.057)
JWD1P (per 1,000 person-hours) 0.359 (0.200, 0.508) 0.457 (0.263, 0.651) 0.542 (0.317, 0.767)
JWS2P (per 1,000 person-hours) 0.011 (−0.002, 0.024) 0.117 (−0.002, 0.025)
JWD2P (per 1,000 person-hours) −0.011 (−0.021, −0.00007) −0.012 (−0.023, −0.001)
JWS1P X Sex(male) (per 1,000
person-hours)
0.168 (−0.259, 0.595)
JW1P X Sex(male) (per 1,000
person-hours)
−0.184 (−0.478, 0.109)
Has most severe cancer (Brain)∗ 1.07 (−0.012, 2.151) 1.028 (−0.054, 2.109) 1.008 (−0.074, 2.09) 1.015 (−0.067, 2.098)
Has least severe cancer
(Prostate)∗
−3.965 (−5.133, −2.797) −4.012 (−5.181, −2.843) −4.015 (−5.184, −2.846) −4.057 (−5.227, −2.887)
Seen by oncologist with best
average outcomes†
−2.025 (−4.344, 0.293) −2.093 (−4.41, 0.224) −2.09 (−4.41, 0.23) −2.121 (−4.448, 0.206)
Seen by oncologist with worst
average outcomes†
0.913 (0.074, 1.752) 0.903 (0.062, 1.744) 0.919 (0.076, 1.761) 0.918 (0.076, 1.76)
∗Also adjusted for 18 other primary cancer types, including unspeciﬁed as one type.
†Also adjusted for 22 other physicians with at least 10 spells as the admission consultant.
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In Model 2, the 1-path inﬂuence parameters show a beneﬁcial eﬀect of neighboring
patients having survived for 5-years (−0.346 CI: −0.540, −0.152) (JWS1P ), and
an adverse eﬀect of neighboring patients having died within 5-years (0.359 CI:
0.200, 0.508) (JWD1P ). Thus, there appears to be both positive and negative direct
inﬂuence based on the health status of those one spends time with. Since these
are per 1,000 Jaccard-weighted person-hours, and patients had an average of 698
Jaccard-weighted person-hours with patients surviving at least 5 years, patients will
have the log-likelihood of mortality modiﬁed by an average of −0.232. Patients
experienced an average of 1,119 Jaccard-weighted person-hours of overlap with
patients surviving less than 5 years, the average patient’s log-likelihood of mortality
increased by 0.401 based on this direct eﬀect. When considering 2-path inﬂuence, the
eﬀects of non-transitive two paths to patients surviving at least 5 years survival is not
signiﬁcant (JWS2P ), but the result for non-transitive two paths with patients dying
within 5 years was signiﬁcant in Model 3 (−0.011 CI: −0.021, −0.00007) (JWD2P ).
This latter result indicates some evidence of inﬂuence through open 2-paths. Finally,
there is no signiﬁcant moderating eﬀect of sex (Model 4).
To illustrate the inﬂuence of co-presence in the chemotherapy ward, we present
the predicted probabilities from Model 2, for three hypothetical patients at varying
levels of risk (Figure 2). The low, medium, and high-risk patients had predicted
probabilities of death of approximately 23%, 69%, and 91%, respectively. For low-
and medium-risk patients, we observe approximately a 2% change in predicted
survival when comparing patients with no co-presence with those co-present with
only patients having one type of outcome (survival or death). However, when
patients are co-present with patients who die and patients who survive, their eﬀect,
on average, results in a minor decrease in predicted probability of survival for
the patient. For the high-risk patient, smaller changes in predicted probability are
observed due to the high baseline risk of death.
Our robustness analyses are, on average, consistent with our main ﬁndings. There
are a few exceptions (Table S2 and Figure S2). Notably, the direct eﬀect of co-
presence with patients surviving 5 years is not signiﬁcant when using an outcome
of survival time instead of dichotomous survival. However, this analysis does not
adequately adjust for intra-patient correlations. Additionally, the sensitivity analysis
for nurse heterogeneity parallels the reduced robustness of the direct eﬀect of co-
presence with patients who survive at least 5 years evident from the survival analysis,
assuming our simulation model adequately captures nurse-induced heterogeneity.
4 Discussion
In the current paper, we investigated whether cancer patient survival is associated
with the survival of those with whom they are co-present during chemotherapy
treatment. Our results suggest that co-presence matters. We ﬁnd that a connected
patient’s death increases the likelihood of the focal actor dying, and a connected
patient’s survival decreases the focal actor’s chance of death. These results are
approximately symmetric; being connected to a single survivor is similarly protective
as being connected to a single non-survivor is deleterious to patient survival. There
are no signiﬁcant results for interactions between Jaccard-weighted person-hours
and patient’s sex, which is not what we expected given previous ﬁndings (Shor &
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Fig. 2. Predicted probability of 5-year mortality for patients with varying risk proﬁles and
potential for social inﬂuence. Across panels, the ﬁrst bar represents the predicted probability
from model 4 with 0 for all inﬂuence terms. The average patient was one who had the
median values for all covariates (rounded for dichotomous and categorical variables). This
equates to a 69-year-old female whose chemotherapy lasted nine visits over 3 months and
spent 30 hours in the ward starting in 2005, with a single diagnosis of a tumor of the ovaries.
The low-risk and high-risk patients had values based on the ﬁrst and third-quartile of the
covariates depending on whether the relationship between 5-year mortality and the covariate
was negative or positive, respectively. The low-risk patient was a 61-year-old female who
visited the ward nine times over the course of a month and spent 30 hours in the ward
starting in 2007, with a single tumor of the breast. The high-risk patient was a 79 year-old
male whose chemotherapy included two visits to the ward over 4 months and spent 30 hours
in the ward starting in 2003, whose primary diagnosis was cancer of the stomach, but had
multiple cancer diagnoses. It is important to stress that these patients are not necessarily
observed in these exact combinations of covariates; they are chosen in the way they were
to demonstrate heterogeneity of the predicted probability of survival. Within each panel,
inﬂuence terms were given the rounded mean value for the variable in question (refer to
Table 2). No inﬂuence means the patient was co-present with no-one (never actually observed
but gives a baseline probability). “Alters survive” means a patient was only co-present with
patients surviving at least 5 years, and “alters die” means a patient was only co-present with
patients dying within 5 years. “Both” means a patient was co-present with both types of
patients.
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Roelfs, 2015). However, our study takes place in a previously unexplored social
environment, so diﬀerent mechanisms may be at play. Placing the results of this
study in the context of cancer treatment, the magnitude of these results (Figure 2)
is less than that of chemotherapy clinical trials but still clinically meaningful.
Here, we observe a survival diﬀerential of 2% for patients at low to moderate
risk when comparing no co-presence vs only co-presence with surviving patients,
whereas eﬀective chemotherapy clinical trials report survival diﬀerences of around
8% (Grabenbauer et al., 1993; Rapp et al., 1988). In eﬀect, chemotherapy patient
survival may be modiﬁed by one-quarter the quantity of the eﬀect of the choice of
chemotherapy.
Regarding the 2-path variables, we observe a non-signiﬁcant result for the Jaccard-
weighted person-hours to surviving patients two-steps away. At the same time, we
found a signiﬁcant eﬀect of the Jaccard-weighted person-hours to patients dying
within 5 years two-steps away, albeit marginally. As such, it would, therefore, only
take a minimal amount of latent confounding between patients to remove that eﬀect
while leaving the main eﬀect signiﬁcant. Given the small magnitude of this eﬀect
and its signiﬁcance level, even a small amount of measurement error could result in
this ﬁnding. Therefore, we believe that the 2-path inﬂuence variables reinforce our
main ﬁndings. However, future research should aim to more thoroughly test if this,
and other network eﬀects not measured here are in fact at play.
Based on the above results, the mechanism by which social inﬂuence occurs
becomes clearer. We observe no signiﬁcant association between total person-hours
of overlap and one’s outcome, indicating that solely being around more people for
more time on its own does not aﬀect one’s health. In this context, just being around
others receiving treatment with similar stressors does not seem to impart any health
eﬀects suggesting that social facilitation and social support are not the underlying
inﬂuence mechanism. Previous research suggests that only 2/3rds of chemotherapy
patients in the United Kingdom indicated receiving adequate emotional support from
hospital staﬀ (NHS, 2014). Thus, many patients may be actively seeking but not
receiving support from others, particularly other patients, during treatment. Future
research should therefore focus on whether and how support networks emerge in
chemotherapy wards to elucidate the content of interactions we have detected via
co-presence here. The inﬂuence eﬀects between connected patients, on the other
hand, likely reﬂect mechanisms where one’s outcome is related to the outcome of
others, where either co-present patients form social relationships, or they observe
others’ health trajectories. The mere observation of other cancer patients’ health
changes over time may inﬂuence the observer’s own stress regarding their own
cancer prognosis and subsequent health (Croyle & Hunt, 1991). This process is akin
to social modeling; however, one may not consciously be altering how they respond
to treatment. Rather, patients may see others doing better or worse, which might
decrease or increase their stress, respectively, which in turn can impact their health.
Although network disruption was possible, it is unlikely that it is the mechanism
given our results. If patients being removed from chemotherapy caused disruption
to other patients’ networks in the ward, then we would expect to see adverse eﬀects
of focal actors’ neighbors ﬁnishing chemotherapy regardless of their neighbors’
outcomes. Instead we observe connected patient’ outcomes are positively correlated,
indicating network disruption is not the mechanism underlying our ﬁndings.
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Since the data used herein are observational, our results may stem from unmea-
sured confounding. We address the two forms we believe have the greatest potential
to explain our results, but this is not an exhaustive list. First, patients may know
one another prior to entering the ward, and any “social inﬂuence” observed here is
the result of social interaction and inﬂuence outside of the chemotherapy ward due
to preexisting social ties. If true, we detect social inﬂuence outside the chemotherapy
ward via the measure of co-presence and in the presence of large amounts of noise.
However, as we show in the Supplementary Information, we believe that the number
of ties due to pre-existing relationships is likely minimal, limiting the eﬀect this
could have on our results. Second, nurse heterogeneity may explain our results if
related both to patient outcomes and co-presence between patients. All of the nurses
in the ward are specially trained as chemotherapy nurses, which would ideally
limit heterogeneity across nurses (National Health Service, 2000). Furthermore,
given our sensitivity analysis assuming nurse eﬀects are on the same order of
magnitude as physician eﬀects (SI), we observe that our results are robust to nurse
heterogeneity. Alternatively, if nursing eﬀects (due to either nurse heterogeneity or
other endogenous factors such as understaﬃng) do in fact explain our results,
then we have detected meaningful nurse eﬀects on patient survival previously
not reported in the literature. Such potential eﬀects should be investigated in the
future.
With the above limitations in mind, this research has potentially important
implications for the study of social networks. Whatever the underlying mechanism,
we detect inﬂuence eﬀects based solely on co-presence data from administrative
records, which is much more eﬃcient to gather than detailed relationship data.
Although one may ask whether the ties used here really represent meaningful social
ties, a recent survey found that 78% of patients in Britain said they would prefer to be
treated in a communal setting indicating that patients feel they beneﬁt from in close
proximity to other patients (NHS, 2013). Thus, consistent co-presence represents the
opportunity for patients to develop meaningful social ties during treatment. While
it is unknown whether such ties developed amongst the patients studied here, it is
clear that there is evidence of social inﬂuence among those who are consistently
co-present. Moreover, we have employed a variety of novel approaches in our eﬀort
to rule out alternative explanations of our main ﬁndings. Future researchers may
ﬁnd our use of rank-order cancer diagnosis, cancer severity, physician eﬀects, and
holistic robustness checks valuable in their own work.
Our results imply that co-presence relates to health in the context of the
chemotherapy ward. However, given the observed negative eﬀects and possibility of
unmeasured confounding, implementing changes to the ward and patient scheduling
to beneﬁt from this knowledge is diﬃcult. If the observed social inﬂuence operates
via changes to stress, then reducing patient stress in the ward without changing
patient scheduling may be able to positively impact all patients. Oncologists can
consider whether social inﬂuence may be at play in the wards to which they
admit patients for chemotherapy, and whether scheduling to maximize co-presence
of patients would sui generis be therapeutic. Given evidence that cancer support
groups improve survival, patients could also be encouraged to engage in social
support while in the chemotherapy ward, which could reduce stress (Cobb, 1976;
Maria et al., 2004). Altering chemotherapy in this way can mitigate the deleterious
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eﬀects of co-presence with patients experiencing negative outcomes and strengthen
the positive eﬀects of co-presence with surviving patients.
With these future directions and applications in mind, the ﬁndings in this paper
are an important ﬁrst step in describing the possibility of social inﬂuence occurring
among patients co-present in a chemotherapy ward; a setting primarily for biological
treatment, not treatment through social support and inﬂuence processes. Importantly,
because we focus on mere co-presence, any ﬁndings not due to unmeasured
confounding are likely to under-estimate the eﬀect of social forces on health
outcomes as co-presence represents the minimally necessary condition for inﬂuence.
We hypothesize that the mechanism of this inﬂuence is mediated by stress response
to co-presence with familiar others. Future research should focus on measurement
of individual coping and stress processes in these settings to test this hypothesis
directly.
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